Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
复制标题
恩格列净对 2 型糖尿病或糖尿病前期以及射血分数降低心力衰竭 (SUGAR-DM-HF) 患者肾脏生化和影像学结果的影响。
DOI：
10.1161/circulationaha.122.059851
复制
发表时间：
2022
期刊：
影响因子：
37.8
通讯作者：
Lee MMY
中科院分区：
文献类型：
--
作者：
Lee MMY
钠-葡萄糖协同转运蛋白2（SGLT 2）抑制剂可降低心力衰竭和射血分数降低（HFrEF）患者肾功能恶化的风险。[1]在随机对照试验的背景下，关于这些药物对肾脏灌注的影响知之甚少。我们使用肾脏磁共振成像（MRI）研究了这些药物的作用。我们进行了一项随机、双盲、安慰剂对照试验，研究恩格列净在纽约心脏协会心功能分级II至IV级、左心室射血分数≤ 40%和2型糖尿病或前驱糖尿病患者中的作用。患者以1：1的比例随机分配至恩格列净10 mg每日一次组或安慰剂组。研究设计、筛选、同意过程、伦理批准和主要结果均已发表。2该研究获得了伦理委员会的批准，所有参与者都签署了书面知情同意书。数据可应要求提供。预先设定的结果包括肾脏MRI生物标志物（肾脏MRI生物标志物）从基线到36周的变化。
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of worsening kidney function in patients with heart failure and reduced ejection fraction (HFrEF). 1 Comparatively little is known about the effects of these drugs on kidney perfusion in the setting of randomized controlled trials. We studied effects of these drugs using kidney magnetic resonance imaging (MRI).We conducted a randomized, double-blind, placebocontrolled trial investigating the effects of empagliflozin in patients with New York Heart Association functional class II to IV, left ventricular ejection fraction≤ 40%, and type 2 diabetes or prediabetes. Patients were randomly assigned 1: 1 to empagliflozin 10 mg daily or placebo. The study design, screening, consent process, ethical approvals, and main results are published. 2 The study had ethical committee approval, and all participants gave written informed consent. Data may be available on request. Prespecified outcomes included change from baseline to 36 weeks in kidney MRI biomarkers (kidney
DOI：
10.1007/s10334-019-00809-4
发表时间：
2020-02-01
影响因子：
2.3
作者：
Rankin, Alastair J.;Allwood-Spiers, Sarah;Gillis, Keith A.
通讯作者：
Gillis, Keith A.